Overview

Trial of Andexanet in Patients Receiving an Oral FXa Inhibitor Who Require Urgent Surgery

Status:
Recruiting
Trial end date:
2022-10-31
Target enrollment:
Participant gender:
Summary
Prospective, open-label clinical trial to evaluate the efficacy and safety of andexanet alfa patients who require urgent surgery that have been anticoagulated with the FXa (activated factor X) inhibitors.
Phase:
Phase 2
Details
Lead Sponsor:
Alexion Pharmaceuticals
Portola Pharmaceuticals